<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04890626</url>
  </required_header>
  <id_info>
    <org_study_id>PanCOVID</org_study_id>
    <nct_id>NCT04890626</nct_id>
  </id_info>
  <brief_title>Clinical Trial to Evaluate the Efficacy of Different Treatments in Patients With COVID-19</brief_title>
  <official_title>Randomized Clinical Trial to Evaluate the Efficacy of Different Treatments in Patients With COVID-19</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Instituto de Investigación Hospital Universitario La Paz</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Instituto de Investigación Hospital Universitario La Paz</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Currently COVID-19 is an international public health emergency. Most COVID-19 patients have&#xD;
      mild or uncomplicated disease, but approximately 14% develop severe disease that requires&#xD;
      hospitalization and oxygen therapy, and up to 5% of patients require admission to Intensive&#xD;
      Care Units.&#xD;
&#xD;
      To date, the only treatments that have shown efficacy in a clinical trial are remdesivir and&#xD;
      dexamethasone. The main objective is to provide reliable estimates on the effects of&#xD;
      different treatment strategies on the outcome and mortality of patients with SARS-CoV-2&#xD;
      infection.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 4, 2020</start_date>
  <completion_date type="Anticipated">November 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">November 30, 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Main randomization. Patients will be randomized to Emtricitabine / Tenofovir disoproxil fumarate or no treatment.&#xD;
Rescue randomization: patients with oxygen requirements, O2 Sat &lt;95% at any time, and at least one of the following inflammation markers: IL-6, CRP, D-dimer, LDH or ferritin above the upper limit of the normal range. Arms:&#xD;
dexamethasone + Baricitinib&#xD;
dexamethasone</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mortality</measure>
    <time_frame>at 28 days</time_frame>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">2193</enrollment>
  <condition>SARS-CoV-2 Infection</condition>
  <arm_group>
    <arm_group_label>Main randomization.Arm: Emtricitabine / Tenofovir disoproxil fumarate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Emtricitabine / Tenofovir disoproxil fumarate</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Main randomization.Arm: No treatment</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>No treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Rescue randomization: Arm: Dexamethasone + Baricitinib</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Rescue randomization: patients with oxygen requirements, O2 Sat &lt;95% at any time, and at least one of the following inflammation markers: IL-6, CRP, D-dimer, LDH or ferritin above the upper limit of the normal range. Arms: Dexamethasone + Baricitinib or Dexamethasone.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Rescue randomization: Arm: Dexamethasone</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Rescue randomization: patients with oxygen requirements, O2 Sat &lt;95% at any time, and at least one of the following inflammation markers: IL-6, CRP, D-dimer, LDH or ferritin above the upper limit of the normal range. Arms: Dexamethasone + Baricitinib or Dexamethasone.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Emtricitabine/Tenofovir Disoproxil Fumarate 200 MG-245 MG Oral Tablet [TRUVADA]</intervention_name>
    <description>Main randomization</description>
    <arm_group_label>Main randomization.Arm: Emtricitabine / Tenofovir disoproxil fumarate</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Baricitinib + dexamethasone</intervention_name>
    <description>Rescue randomization</description>
    <arm_group_label>Rescue randomization: Arm: Dexamethasone + Baricitinib</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone</intervention_name>
    <description>Rescue randomization</description>
    <arm_group_label>Rescue randomization: Arm: Dexamethasone</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        First randomization&#xD;
&#xD;
        Inclusion criteria.&#xD;
&#xD;
          -  Men and women agree to participate in the study by signing the informed consent.&#xD;
&#xD;
          -  Men and women aged ≥ 60 years.&#xD;
&#xD;
          -  Men and women aged ≥18 years &lt;60 years with ≥ 2 comorbidities of the following:&#xD;
             hypertension, obesity, diabetes, cirrhosis, chronic neurological disease, active&#xD;
             cancer, heart failure, ischemic heart disease, COPD.&#xD;
&#xD;
          -  Patient with a diagnosis of SARS-CoV-2 infection confirmed by PCR or rapid diagnostic&#xD;
             test prior to randomization.&#xD;
&#xD;
          -  Patients with symptoms and signs compatible with active infection.&#xD;
&#xD;
          -  Men and women of reproductive capacity must agree to use highly effective&#xD;
             contraceptive methods (diaphragm plus spermicide or male condom plus spermicide, oral&#xD;
             contraceptive combined with a second method of contraceptive implant, injectable&#xD;
             contraceptive, permanent intrauterine device, sexual abstinence or vasectomy) during&#xD;
             your participation in the study and within 30 days of the last visit.&#xD;
&#xD;
          -  In addition, women participating in the study with reproductive capacity must have a&#xD;
             negative pregnancy test at the time of inclusion.&#xD;
&#xD;
        Exclusion criteria.&#xD;
&#xD;
          -  Patients participating in any other clinical trial with drugs with potential antiviral&#xD;
             action for SARS-CoV-2&#xD;
&#xD;
          -  Concomitant treatment with drugs other than the treatments included in this study with&#xD;
             demonstrated or potential action against SARS-CoV-2 in the 24 hours prior to the&#xD;
             administration of the study treatment.&#xD;
&#xD;
          -  Patients who are already receiving any of the study drugs.&#xD;
&#xD;
          -  Patients treated with corticosteroids at immunosuppressive doses (15 mg / day in the 7&#xD;
             days prior to the onset of symptoms).&#xD;
&#xD;
          -  Evidence of multi-organ failure.&#xD;
&#xD;
          -  HIV positive, confirmed by rapid test before inclusion.&#xD;
&#xD;
          -  Patients who require reservoir, mechanical ventilation or present acute respiratory&#xD;
             distress criteria at the time of inclusion.&#xD;
&#xD;
          -  ALT or AST&gt; 5 times the upper limit of normal during screening.&#xD;
&#xD;
          -  Creatinine clearance less than 60 ml / min during screening.&#xD;
&#xD;
          -  Pregnancy test with positive result during screening.&#xD;
&#xD;
          -  Women who are breastfeeding.&#xD;
&#xD;
          -  Patients with known hypersensitivity to any of the drugs in the treatment branches of&#xD;
             the study, their metabolites or excipients.&#xD;
&#xD;
          -  Patients who receive medication incompatible with the study drugs after reviewing&#xD;
             possible interactions.&#xD;
&#xD;
          -  Patients who present any contraindication or condition that is included in the section&#xD;
             on warnings and special precautions for the use of the technical sheets of the drugs&#xD;
             under study (Emtricitabine / Tenofovir disoproxil, and remdesivir) or any other reason&#xD;
             that the research team has criteria is reason. not to be included in the study.&#xD;
&#xD;
          -  Subjects who are not able to understand the information sheet and are unable to sign&#xD;
             the informed consent&#xD;
&#xD;
        Second randomization (if applicable):&#xD;
&#xD;
        Patients already included in the study and initially randomized may be re-randomized at any&#xD;
        time if they present an O2 Sat &lt;95% (need for oxygen therapy) and at least 1 marker of&#xD;
        inflammation of the following: IL-6, CRP, D-Dimer , LDH, or ferritin above the upper limit&#xD;
        of the normal range. This randomization can only be done in hospitalized patients. Patients&#xD;
        will receive one of the following arms of treatment:&#xD;
&#xD;
          -  Baricitinib and dexamethasone&#xD;
&#xD;
          -  Dexamethasone&#xD;
&#xD;
        Exclusion criteria (rescue randomization):&#xD;
&#xD;
          -  Non-hospitalized patient&#xD;
&#xD;
          -  Being receiving cytotoxic or biological treatments (such as TNF inhibitors, anti&#xD;
             interleukin 1, anti-interleukin 6 (tocilizumab or sarilumab), therapies against B or T&#xD;
             cells (rituximab), interferon or Janus kinase inhibitors.&#xD;
&#xD;
          -  Have ever received convalescent plasma or intravenous immunoglobulins.&#xD;
&#xD;
          -  Suspicion of suffering from another serious bacterial, fungal or viral infection in&#xD;
             addition to COVID-19 that in the opinion of the researcher could be a risk to receive&#xD;
             the research products.&#xD;
&#xD;
          -  Have received a live vaccine 4 weeks before screening&#xD;
&#xD;
          -  Require mechanical ventilation or ECMO&#xD;
&#xD;
          -  Patient with a history of thromboembolic disease: deep vein thrombosis and / or&#xD;
             pulmonary embolism within 12 weeks prior to randomization or have a history of&#xD;
             recurrent thromboembolic disease&#xD;
&#xD;
          -  Neutropenia &lt;1000 cells / μL&#xD;
&#xD;
          -  Lymphopenia &lt;200 cells / μL&#xD;
&#xD;
          -  GOT or GPT&gt; 5 times the upper limit of normal&#xD;
&#xD;
          -  MDRD &lt;30 mL / min&#xD;
&#xD;
          -  History of hypersensitivity to baricitinib or its components.&#xD;
&#xD;
          -  Pregnant or planning pregnancy or lactating during the study&#xD;
&#xD;
          -  Are using or will be using a blood purification instrument to remove pro-inflammatory&#xD;
             cytokines.&#xD;
&#xD;
          -  A life expectancy &lt;48 hours from screening.&#xD;
&#xD;
          -  Contraindication to take the study medication or investigator criteria.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Dr. José Ramón Arribas, MD</last_name>
    <phone>0034 91 727 70 99</phone>
    <phone_ext>47099</phone_ext>
    <email>joser.arribas@salud.madrid.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Dr. Alberto M. Borobia, MD</last_name>
    <email>alberto.borobia@salud.madrid.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hospital Universitario La Paz</name>
      <address>
        <city>Madrid</city>
        <zip>28046</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jose Ramón Arribas López, MD</last_name>
      <phone>0034 91 727 70 99</phone>
      <phone_ext>47099</phone_ext>
      <email>joser.arribas@salud.madrid.org</email>
    </contact>
    <contact_backup>
      <last_name>Victoria Hernandez Rubio</last_name>
      <phone>0034 914972729</phone>
      <email>victoria.hernandez.ucicec@gmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>José Ramón Arribas, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <link>
    <url>http://pancovidtrial.net/</url>
    <description>Related Info</description>
  </link>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>May 17, 2021</study_first_submitted>
  <study_first_submitted_qc>May 17, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 18, 2021</study_first_posted>
  <last_update_submitted>May 18, 2021</last_update_submitted>
  <last_update_submitted_qc>May 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>COVID-19</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tenofovir</mesh_term>
    <mesh_term>Emtricitabine</mesh_term>
    <mesh_term>Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>BB 1101</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

